Tags

Type your tag names separated by a space and hit enter

Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease.
Expert Rev Respir Med. 2015 Feb; 9(1):5-12.ER

Abstract

Fluticasone furoate/vilanterol (FF/VI) is a novel inhaled corticosteroid/long-acting β₂-agonist (ICS/LABA) fixed dose combination that, by simplifying the dosing schedule, allows, for the first time in a member of the ICS/LABA class, a shift from twice-daily to once-daily treatment. FF/VI is delivered via a novel, single-step activation, multi-dose dry powder inhaler for oral inhalation, Ellipta. Regrettably, there are no head-to-head trials that have shown superiority in the safety or efficacy of FF versus other ICSs, but evidence shows that VI has a quicker onset of effect versus salmeterol. However, the clinical utility of this effect in a maintenance medication is still questionable. Furthermore, benefits of FF/VI over twice-daily ICS/LABA comparator have not been shown yet and, in addition, its adverse event profile is generally consistent with the known class effects of an ICS/LABA fixed dose combination. In particular, there is an increase in the risk of pneumonia among patients treated with FF/VI relative to VI, mainly among those who benefit most from FF/VI. Nevertheless, the interesting pharmacological profiles of both FF and VI, the possibility that FF/VI can be administered once-daily, and the attractive characteristics of Ellipta are important features that could help FF/VI to be a successful combination in the treatment of chronic obstructive pulmonary disease.

Authors+Show Affiliations

Department of Experimental Medicine, Section of Pharmacology 'L. Donatelli', Centre of Excellence for Cardiovascular Diseases, Second University of Naples, Naples, Italy.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

25482512

Citation

Matera, Maria Gabriella, et al. "Fluticasone Furoate and Vilanterol Inhalation Powder for the Treatment of Chronic Obstructive Pulmonary Disease." Expert Review of Respiratory Medicine, vol. 9, no. 1, 2015, pp. 5-12.
Matera MG, Capuano A, Cazzola M. Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease. Expert Rev Respir Med. 2015;9(1):5-12.
Matera, M. G., Capuano, A., & Cazzola, M. (2015). Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine, 9(1), 5-12. https://doi.org/10.1586/17476348.2015.986468
Matera MG, Capuano A, Cazzola M. Fluticasone Furoate and Vilanterol Inhalation Powder for the Treatment of Chronic Obstructive Pulmonary Disease. Expert Rev Respir Med. 2015;9(1):5-12. PubMed PMID: 25482512.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease. AU - Matera,Maria Gabriella, AU - Capuano,Annalisa, AU - Cazzola,Mario, Y1 - 2014/12/06/ PY - 2014/12/9/entrez PY - 2014/12/9/pubmed PY - 2015/9/17/medline KW - COPD KW - Ellipta KW - fixed-dose combination KW - fluticasone furoate KW - vilanterol SP - 5 EP - 12 JF - Expert review of respiratory medicine JO - Expert Rev Respir Med VL - 9 IS - 1 N2 - Fluticasone furoate/vilanterol (FF/VI) is a novel inhaled corticosteroid/long-acting β₂-agonist (ICS/LABA) fixed dose combination that, by simplifying the dosing schedule, allows, for the first time in a member of the ICS/LABA class, a shift from twice-daily to once-daily treatment. FF/VI is delivered via a novel, single-step activation, multi-dose dry powder inhaler for oral inhalation, Ellipta. Regrettably, there are no head-to-head trials that have shown superiority in the safety or efficacy of FF versus other ICSs, but evidence shows that VI has a quicker onset of effect versus salmeterol. However, the clinical utility of this effect in a maintenance medication is still questionable. Furthermore, benefits of FF/VI over twice-daily ICS/LABA comparator have not been shown yet and, in addition, its adverse event profile is generally consistent with the known class effects of an ICS/LABA fixed dose combination. In particular, there is an increase in the risk of pneumonia among patients treated with FF/VI relative to VI, mainly among those who benefit most from FF/VI. Nevertheless, the interesting pharmacological profiles of both FF and VI, the possibility that FF/VI can be administered once-daily, and the attractive characteristics of Ellipta are important features that could help FF/VI to be a successful combination in the treatment of chronic obstructive pulmonary disease. SN - 1747-6356 UR - https://www.unboundmedicine.com/medline/citation/25482512/Fluticasone_furoate_and_vilanterol_inhalation_powder_for_the_treatment_of_chronic_obstructive_pulmonary_disease_ L2 - https://www.tandfonline.com/doi/full/10.1586/17476348.2015.986468 DB - PRIME DP - Unbound Medicine ER -